Small molecule designed to target metal binding site in the alpha 2I domain inhibits integrin function



: Kapyla J, Pentikainen OT, Nyronen T, Nissinen L, Lassander S, Jokinen J, Lahti M, Marjamaki A, Johnson MS, Heino J,

Publisher: AMER CHEMICAL SOC

: 2007

: Journal of Medicinal Chemistry

: JOURNAL OF MEDICINAL CHEMISTRY

: J MED CHEM

: 50

: 11

: 2742

: 2746

: 5

: 0022-2623

DOI: https://doi.org/10.1021/jm070063t(external)

: http://pubs.acs.org/doi/abs/10.1021/jm070063t(external)


Integrin alpha 2 beta 1 is a potential target molecule in drug development. We have established "design" criteria for molecules that bind to the "closed" conformation of alpha 2I domain via Mg2+ in MIDAS (metal ion dependent adhesion site) while simultaneously forming interactions with neighboring amino acid residues. Specific tetracyclic Streptomyces products belonging to the group of aromatic polyketides fulfill our criteria and inhibit alpha 2 beta 1 integrin. All previously described inhibitors of alpha I domain integrins act in an allosteric manner.



Last updated on 2024-26-11 at 23:52